Clinical Trial Details

< Previous Trial     Next Trial >
Study ID ENT0016
Investigator
Quynh-Thu Le,   Stanford University
Title Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Conditions Head and Neck Cancer
Lung Cancer
Lip Cancer
Lip Neoplasms
Head and Neck Cancers
Interventions Procedure: Tumor biopsy
Procedure: Phlebotomy
Phase N/A
Purpose The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Both
Accepts Healthy Volunteers:  No
Inclusion Criteria:Newly diagnosed patients with head and neck cancer who has tumor accessible to tumor oxygenation measurement with a microelectrode.
Study Location
Stanford University School of Medicine
Stanford, California, 94305
Contact Cato Chan
650-724-4606
catochan@stanford.edu
Information objtained from ClinicalTrials.gov, on 8/28/2014. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568490


Back to Search Results